1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 2013;127: e6–245.
2. Fonarow GC. ADHERE Scientific Advisory Committee. The ADHF National Registry (ADHERE): opportunities to improve care of patients hospitalized with ADHF. Rev Cardiovasc Med 2003;4(suppl 7):S21-S30.
3. Philbin EF, Dec GW, Enkins PL, et al. Socioeconomic status as an independent risk factor for hospital readmission for heart failure. Am J Cardiol 2001;87:1367–71.
4. Weintraub NL, Collins SP, Pang PS, et al.; on behalf of the American Heart Association Council on Clinical Cardiology and Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. Circulation 2010;122:1975–96.
5. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-239.
6. Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003;41:1797–1804.
7. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161–7.
8. Fonarow GC, Peacock WF, Phillips CO, et al. ADHERE Scientific Advisory Committee and Investigators. Admission B-type natriuretic peptide levels and in-hospital mortality in ADHF. J Am Coll Cardiol 2007;49:1943–50.
9. Logeart D, Thabut G, Jourdian P, et al. Pre-discharge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004;43:635–41.
10. Peacock WFIV, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008;358:2117–26.
11. Ilva T, Lassus J, Siirila-Waris K, et al. Clinical significance of cardiac troponins I and T in acute heart failure. Eur J Heart Fail 2008;10:772–9.
12. Peterson PN, Rumsfeld JS, Liang L, et al. A validated risk score for inhospital mortality in patients with heart failure from the American Heart Association Get With The Guidelines program. Circ Cardiovasc Qual Outcomes 2010;3:25–32.
13. Fonarow GC, Adams KF, Abraham WT, et al, for the ADHERE Scientific Advisory Committee, Study Groups and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005;293:572–80.
14. Felker GM, Leimberger JD, Califf RM, et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail 2004;10:460–6.
15. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003;290:2581–7.
16. Abraham WT, Fonarow GC, Albert NM, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure. J Am Coll Cardiol 2008; 52:347–56.
17. Gheorghiade M, Shin DD, Thomas TO, et al. Congestion is an important diagnostic and therapeutic target in heart failure. Rev Cardiovasc Med 2006;7(suppl l):S12-S24.
18. Peacock WF, Emerman C, Costanzo MR, et al. Early vasoactive drugs improve heart failure outcomes. Congest Heart Fail 2009;15:256–64.
19. Maisel AS, Peacock WF, McMullin N, et al. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE analysis. J Am Coll Cardiol 2008;52:534–40.
20. Salvador DRK, Rey NR, Ramos GC, et al. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005(3):CD003178.
21. Pivac N, Rumboldt Z, Sardelic S, et al. Diuretic effects of furosemide infusion versus bolus injection in congestive heart failure. Int J Clin Pharmacol Res 1998;18:121–8.
22. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with ADHF. N Engl J Med 2011;364:797–805.
23. Cotter G, Metzkor E, Kaluski E, et al. Randomized trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary edema. Lancet 1998;351:389–93.
24. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004;147:331–8.
25. Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in ADHF (DAD-HF) Trial. J Card Fail 2010;16:922–30.
26. Cotter G, Weissgarten J, Metzkor E, et al. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther 1997;62:187–93.
27. Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 2013;310:2533–43.
28. Costanzo MR, Saltzberg M, O’Sullivan J, et al. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol 2005;46:2047–51.
29. Costanzo MR, Guglin ME, Saltzberg MT, et al; UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for ADHF. J Am Coll Cardiol 2007;49:675–83.
30. Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012;367:2296-304.
31. Shrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577–85.
32. Konstam MA, Gheorghiade M, Burnett Jr JC, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319–31.
33. Gheorghiade M, Konstam MA, Burnett Jr JC, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297:1332–43.
34. Goldsmith SR, Elkayam U, Haught WH, et al. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in ADHF: a dose-ranging pilot study. J Card Fail 2008;14:641–-7.
35. Shin DD, Brandimarte F, DeLuca L, et al. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 2007;99:4A–23A.
36. Mattu A, Martinez JP, Kelly BS. Modern management of cardiogenic pulmonary edema. Emerg Med Clin North Am 2005;23:1105–25.
37. Lindenfeld J, Albert NM, Boehmer JP, et al. Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010;16:e475-e539
38. Abraham WT, Adams KF, Fonarow GC, et al. ADHERE Scientific Advisory Committee and Investigators; ADHERE Study Group. In-hospital mortality in patients with ADHF requiring intravenous vasoactive medications: an analysis from the ADHF national registry (ADHERE). J Am Coll Cardiol 2005;46:57–64.
39. Mullens W, Abrahams Z, Francis GS, et al. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol 2008;52:200–7.
40. Bhalla V, Willis S, Maisel AS. B-type natriuretic peptide: the level and the drug-partners in the diagnosis and management of congestive heart failure. Congest Heart Fail 2004;10(1 suppl 1):3–27.
41. Publication Committee for the VMAC investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531–40.
42. O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with ADHF. N Engl J Med 2011;365:32–43.
43. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 2007;153:98–104.
44. Cuffe MS, Califf RM, Adams KF Jr, et al. Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized control trial. JAMA 2002;287:1541–7.
45. Hershberger RE, Nauman D, Walker TL, et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail 2003;9:180–7.
46. Peacock WF, Hollander JE, Diercks DB, et al. Morphine and outcomes in ADHF: an ADHERE analysis. Emerg Med J 2008;25:205–9.
47. Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012;367:1287–96.
48. Abu-Omar Y, Tsui S. Mechanical circulatory support for AMI and cardiogenic shock. J Card Surg 2010;25:434–41.
49. Ziemba EA, John R. Mechanical circulatory support for bridge to decision: which device and when to decide. J Card Surg 2010;25:425–33.
50. Sanchez CE, Richards DR. Contemporary in-hospital management strategies for ADHF. Cardiol Rev 2011;19:122–9.
